PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melanoma. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the first approved checkpoint inhibitor. Emerging long-term data indicate that approximately 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Luke, Jason J., Ott, Patrick A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414130/
https://www.ncbi.nlm.nih.gov/pubmed/25682878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414130/
https://www.ncbi.nlm.nih.gov/pubmed/25682878

Ejemplares similares